April 18, 2007 - An imaging workstation solution from Cedara Software Corp., a division of Merge Healthcare, was recently used in a study published in this week's issue of Cancer Research Journal, focusing on a technique called functional diffusion map, which uses magnetic resonance imaging scanning and Cedara's I-Response solution to measure diffusion of water within tumors.
Study author Brian D. Ross, Ph.D. says there is no current way to detect bone tumor response to therapy, but the functional diffusion map could serve as an early biomarker, indicating that a tumor is responding to treatment, in turn helping patients make decisions about switching to alternative therapy without wasting time on a treatment that is not working.
I-Response is being developed by Cedara, in conjunction with researchers at the University of Michigan Comprehensive Cancer Center.
June 16, 2026 
